Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | PER2 | O15055 | 8/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577145 | 0.95 | PTGDR2 (0.43) | PTGDR2PER2HIF1AKDM4ECYP1A2 | |
| SCHEMBL5576489 | 0.85 | EGLN1 (0.41) | DPP4 | |
| SCHEMBL5233862 | 0.84 | KDM4E (0.40) | PTGDR2KDM4EMAPTTSHR | |
| SCHEMBL5576858 | 0.82 | MAPT (0.43) | PTGDR2KDM4EMAPTHPGDTSHR | |
| SCHEMBL5234504 | 0.81 | PTGDR2 (0.39) | PTGDR2PER2HIF1ACRY1CRY2 | |
| SCHEMBL5239883 | 0.80 | PTGDR2 (0.40) | PTGDR2KDM4EMAPTTSHR | |
| SCHEMBL5237316 | 0.79 | PTGER4 (0.37) | PTGDR2KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL5232796 | 0.77 | PTGDR2 (0.39) | PTGDR2KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL5577112 | 0.73 | MAPK8 (0.47) | HIF1ACRY1CRY2 | |
| SCHEMBL5235788 | 0.72 | KDM4E (0.41) | KDM4ECYP1A2MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | PTGDR2 440/4885PER2 1459/4885HIF1A 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.